New Directions in Chronic Lymphocytic Leukemia

Article

This publication highlights expert perspectives on the current therapeutic landscape in chronic lymphocytic leukemia with emphasis on factors affecting treatment selection including novel regimens, combination therapies, and ongoing clinical trials.

Related Videos
Jean L. Koff, MD, MS
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Changchun Deng, MD, PhD
Changchun Deng, MD, PhD, associate professor, hematology/oncology, University Hospitals Seidman Cancer Center; member, Immune Oncology Program, Case Comprehensive Cancer Center
Bhagirathbhai Dholaria, MBBS, associate professor, medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center
Jennifer Brown, MD, PhD
Saad J. Kenderian, MB, CHB
Eduardo Sotomayor, MD
Saad J. Kenderian, MB, CHB
Jennifer Brown, MD, PhD
Related Content
Jean L. Koff, MD, MS

Pirtobrutinib Transforms SOC in Later-Line CLL/SLL

May 14th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Matthew S. Davids, MD, MMSc

Acalabrutinib Yields Long-Term Efficacy in a Pooled Analysis of Higher-Risk CLL

May 6th 2024
Article
Talal Hilal, MD, MB, BCh

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

January 12th 2023
Podcast
FDA

FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies

April 19th 2024
Article
Houston Wyatt, Vanderbilt Specialty Pharmacy, Vanderbilt Health

CLL/SLL Therapy Initiation at Specialty Pharmacies May Increase Treatment Adherence Rates

April 18th 2024
Article